StockData

Drugs Made In America Acquisition Corp. (DMAA) stock

DMAANasdaqBlank ChecksFiscal year ends December 31Also trades as DMAAR, DMAAU
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.90+0.00 (0.00%)

Close on Nov 17, 2026Market cap $264.62MP/E –Yield –

Drugs Made In America Acquisition operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Drugs Made In America Acquisition's operating income for the twelve months ending Jun 30, 2026 was -$2.63M. For fiscal 2025 it was -$2.82M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.82M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$136.93K–
Q1 FY2026Mar 31, 2026-$143.30K–
Q4 FY2025Dec 31, 2025-$2.09M–
Q3 FY2025Sep 30, 2025-$263.70K–
Q2 FY2025Jun 30, 2025-$131.92K–
Q1 FY2025Mar 31, 2025-$330.93K–
Q3 FY2024Sep 30, 2024-$144.93K–

More Drugs Made In America Acquisition figures

See a number that looks wrong?